Kyverna Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
About Kyverna Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company concentrates primarily on its neuroimmunology CAR T franchise to achieve immune reset and treatment-free remission. Its lead product candidate is mivocabtagene autoleucel (miv-cel, or KYV-101), an autologous, fully human CD19-targeting CAR T-cell therapy being developed for serious conditions including stiff person syndrome and generalized myasthenia gravis. Additionally, the company explores pipeline expansion into other autoimmune indications such as progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis, as well as novel manufacturing platforms such as KYV-102.
The company's clinical research is supported by data from investigator-initiated trials at leading academic institutions and company-sponsored clinical trials across various autoimmune indications. Kyverna maintains its principal executive offices in Emeryville, California.
Summary of the business section of Kyverna Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Kyverna Therapeutics, Inc.
- Headquarters
- Emeryville, CA
- Address
- 5980 Horton Street, Suite 200
- Phone
- (510) 925-2492
- Website
- kyvernatx.com
- Employees
- 130, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- KYTX
- Exchange
- Nasdaq
- IPO date
- Feb 8, 2024
- Shares outstanding
- 62M, Aug 3, 2026
- Public float
- $64.50M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1994702
- CUSIP
- 501976104
- ISIN
- US5019761049
- EIN
- 83-1365441
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christi Shaw | Executive Chairperson, Director | 66,741 |
| Warner Weston Biddle | Chief Executive Officer, Director | 58,000 |
| Gregory S. Martini | Chief Financial Officer | – |
| Nadia Dac | Chief Commercial Officer | – |
| Marc Grasso | Chief Financial Officer | 10,000 |
| Naji Gehchan | See Remarks | 18,000 |
| Mayobanex Pujols | Chief Technology Officer | – |
| Karen Marie Walker | Chief Technology Officer | 22,636 |
| Ryan Alexander Jones | Chief Financial Officer | 55,950 |
| Fred E. Cohen | Director | 4,545,651 |
| Beth C. Seidenberg | Director | 891,044 |
| Ian T. Clark | Director | 21,727 |
| Mert Aktar | Director | 21,727 |
| Andrew Craig Miller | Director | 11,006 |
| Sravan Kumar Emany | Director | 11,006 |
| Daniel K. Spiegelman | Director | 16,634 |
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had 130 employees, all of whom were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 8, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 5, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |